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Abstract
Genome-wide association studies (GWAS) of late-onset Alzheimer disease (LOAD) have consistently observed strong
evidence of association with polymorphisms in APOE. However, until recently, variants at few other loci with statistically
significant associations have replicated across studies. The present study combines data on 483,399 single nucleotide
polymorphisms (SNPs) from a previously reported GWAS of 492 LOAD cases and 496 controls and from an independent set
of 439 LOAD cases and 608 controls to strengthen power to identify novel genetic association signals. Associations
exceeding the experiment-wide significance threshold (a~1:03|10{7) were replicated in an additional 1,338 cases and
2,003 controls. As expected, these analyses unequivocally confirmed APOE’s risk effect (rs2075650, P~1:9|10{36).
Additionally, the SNP rs11754661 at 151.2 Mb of chromosome 6q25.1 in the gene MTHFD1L (which encodes the
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like protein) was significantly associated with LOAD
(P~4:70|10{8; Bonferroni-corrected P=0.022). Subsequent genotyping of SNPs in high linkage disequilibrium (r2w0:8)
with rs11754661 identified statistically significant associations in multiple SNPs (rs803424, P=0.016; rs2073067, P=0.03;
rs2072064, P=0.035), reducing the likelihood of association due to genotyping error. In the replication case-control set, we
observed an association of rs11754661 in the same direction as the previous association at P=0.002 (P~1:90|10{10 in
combined analysis of discovery and replication sets), with associations of similar statistical significance at several adjacent
SNPs (rs17349743, P=0.005; rs803422, P=0.004). In summary, we observed and replicated a novel statistically significant
association in MTHFD1L, a gene involved in the tetrahydrofolate synthesis pathway. This finding is noteworthy, as MTHFD1L
may play a role in the generation of methionine from homocysteine and influence homocysteine-related pathways and as
levels of homocysteine are a significant risk factor for LOAD development.
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Introduction
Alzheimer disease (AD) [MIM 104300] is a neurodegenerative
disorder characterized by memory and cognitive impairment
affecting more than 13% of individuals aged 65 years and older
[1,2] and constitutes the most common form of dementia among
older adults. While several major genes contributing to risk of
Alzheimer Disease have been identified (APP [3], PS1 [4], PS2 [5–
7]), all but one (APOE [8–10]) contributed predominantly to early-
onset forms of AD that cluster within families; other than APOE, few
consistent association signals have been observed for late-onset AD
(LOAD). Recent estimates of the heritability of LOAD fall between
60% and 80% [11]. However, while APOE e4-alleles elevate AD
risk, only 50% of AD cases carry an APOE e4 allele, suggesting
genetic factors elsewhere in the genome contribute to AD risk [12].
At present, eleven studies have tested association with LOAD on
genome-wide panels of single nucleotide polymorphisms (SNPs).
Most [13–22], but not all [23], of these studies indirectly observed
associations with APOE on chromosome 19q with strong
experiment-wide statistical significance. However, only a few of
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wide statistical significance thresholds. A follow-up study [15] to
Coon et al. [14] stratifying cases and controls by APOE genotype
detected strongassociationswith GAB2 (MIM:606203) SNPs, and in
follow-up work observed altered GAB2 transcript levels in
vulnerable neurons, and an effect of GAB2 levels on tau
phosphorylation; replication studies observed mixed results. In a
family-based studyofLOAD,Bertram etal.[17] observedfourSNP
associations exceeding adjusted experiment-wide thresholds for
statistical significance, including one for the chromosome. Our
group reported a SNP association with experiment-wide statistical
significanceonchromosome 12q13 [18]. A GWASoriginatingfrom
theMayo Clinic[19] identified a novelsignalon the X chromosome
in the gene PCDH11X (MIM: 300246), encoding a protocadherin, a
cell-cell adhesion molecule expressed in the brain. Generally, these
earlier reports have not been consistently replicated in other studies,
possibly due to sample sizes that are substantially smaller than those
of GWAS studies that have successfully identified genes for other
complex disorders [24,25]. Two large collaborative GWAS of
LOADexamined many thousands of casesand controls [20,21]and
both identified novel association signals in the gene CLU (aka APOJ,
MIM: 185430; Apolipoprotein J or Clusterin), as well as signals in
CR1 (MIM: 120620, Complement Component Receptor 1) and in
PICALM (MIM: 603025, Phosphatidylinositol-Binding Clathrin
Assembly Protein), reporting some of the most consistent results for
LOAD to date.
Even with the increased sample sizes and improved statistical
power to detect loci with moderate effect sizes, it remains unlikely
that these studies, incorporating cases and controls from multiple
samples with varying case/control inclusion criteria, have
identified all loci with modest effect sizes in LOAD. We analyzed
genome-wide association in a discovery dataset of 931 cases and
1,104 controls and performed replication analysis on the strongest
associations (P,10
25) using genotype data from four existing
studies totaling 1,338 cases and 2,003 controls.
Results
Dataset Characteristics
Table 1 depicts the demographic characteristics of the case and
control samples examined in initial association analyses. We
examined 931 LOAD cases, average age 74.4 years at onset
(standard deviation: 68.1 years), and 1,104 cognitive controls,
average age 73.8 years at exam (67.8 years) (Table 1). Cases were
64.5% female, while controls were 61.9% female.
GWAS Results
11 SNPs had association p-values (P),10
25 after adjustment for
population substructure (Table 2; Q-Q plot for all association
results in Figure 1; P,10
24 in Tables S1, S2; all association results
in Figure S1). Although the SNPs defining the APOE e2, e3, and e4
alleles, rs429358 and rs7412, were not included on our genotyping
platforms, we independently genotyped these SNPs and tested the
association of APOE e4 with LOAD risk (OR (95% CI): 4.18 (3.51,
4.97); P~5:49|10{58). SNPs adjacent to the APOE haplotype on
chromosome 19 otherwise demonstrated the highest associations
observed, with the peak association being rs2075650 with
P~1:90|10{36, confirming the expected effect of APOE on
LOAD risk in this sample. The most significant non-APOE SNP in
our previous GWAS [18] (Table S3) was rs11610206 on 12q13
(45.92 Mb) with P~1:43|10{6; in this study, this SNP was
still strongly assoFciated with LOAD (OR (95% CI): 0.67 (0.54,
0.85); P~7:70|10{4), but not with experiment-wide statistical
significance.
The SNP rs11754661, located at 151.2Mb of chromosome
6q25.1 in the gene MTHFD1L, was significantly associated with
LOAD (P~4:70|10{8; Bonferroni-corrected P=0.022). To
ensure that this association was not spurious due to differences
between subsets of genotyped samples, we performed several post-
hoc quality control analyses. We examined clustering plots from
Author Summary
Studies looking for genetic variants across the genome
that affect late-onset Alzheimer disease (LOAD) have had
little success identifying genes other than APOE. Here, we
use an expanded set of AD cases and controls to improve
our power to detect genetic variants driving LOAD risk.
Analyzing 483,399 genetic variants across the genome in a
discovery dataset of 931 cases and 1,104 controls, we
found a strong association to the marker rs11754661 on
chromosome 6 in the gene MTHFD1L, in addition to the
highly replicated chromosome 19 APOE association. We
genotyped adjacent variants on chromosome 6 in these
same cases and controls and found these variants were
also associated with LOAD. We replicated the association
with rs11754661 and additional SNPs in MTHFD1L in a
combined dataset of cases and controls from our
laboratory and from publicly available datasets. This
finding is important because the gene is known to be
involved in biological pathways influencing levels of
homocysteine, a significant risk factor for AD.
Table 1. Demographic characteristics of participants in the study sample (mean 6 SD or number (percent)).
All Cases Controls
Number of subjects 2,036 931 1,104
Females (%) 1,284 (63.0%) 601 (64.5%) 683 (61.9%)
Age-at-onset [cases] (yr)/Age-at-exam [controls] (yr) – 74.468.1 73.867.8
APOE e4 carrier status
–/– carriers (0 copies) 1223 (60.1%) 399 (42.8%) 824 (74.6%)
e4/– carriers (1 copy) 629 (30.9%) 398 (42.7%) 231 (20.9%)
e4/e4 carriers (2 copies) 144 (7.1%) 127 (13.6%) 17 (1.5%)
carrier status missing 40 (2.0%) 8 (0.9%) 32 (2.9%)
*Percentage of successfully genotyped single nucleotide polymorphisms (SNPs) among those attempted.
doi:10.1371/journal.pgen.1001130.t001
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have affected the associations observed for the top 11 SNPs with
P,10
25, and observed discrete clustering by genotype for all 11
SNPs. We found noevidence ofa differenceingenotypefrequencies
among controls across subsets by genotyping platform (Fisher’s
exact test P=0.71) or by study center (Fisher’s exact test P=0.95,
Table S4). We also examined differences in dataset characteristics
including variation in age, sex, and APOE e4 genotype distributions,
and found limited differences between subsets by study center,
autopsy- or clinical-confirmation of case or control status, and by
genotyping platform (Table S5). Subsequently, we examined the
first hundred principal components generated from EIGEN-
STRAT to determine if any of the principal components were
associated with both differences in genotyping platform subset and
disease status at P,0.05 as markers of potential systematic bias.
While two principal components other than those used to adjust for
population substructure showed association with both genotyping
platform subset and LOAD, additional adjustment for these
principal components did not change the strength of association
between rs11754661 and LOAD (data not shown). Models further
adjusting for age, sex, and APOE e4 carrier status (+/2) (Table S6)
only marginally diminished the effect size and statistical significance
of the association of rs11754661 with LOAD (adjustment for age
and sex, OR (95% CI): 2.03 (1.56, 2.64), P~1:42|10{7;
adjustment for age, sex and APOE e4( +/2), OR (95% CI): 2.01
(1.51, 2.67), P~1:64|10{6).
Furthermore, we examined the associations in 4 SNPs in linkage
disequilibrium (LD) (Figures S2) of D’.0.8 with rs11754661,
which demonstrated variable patterns of association with LOAD
(Figure 2; rs2839947, P=0.0479; rs11757561, P=0.000684;
rs2073066, P=0.768; rs13201018, P=0.185). It should be noted
that due to the low minor allele frequency (MAF) of rs11754661
(MAF=0.07), only one of these SNPs, rs11757561 (MAF=0.20),
had an r
2.0.10 (r
2=0.23). This SNP had a similar direction of
association as rs11754461 (OR (95% CI): 1.31 (1.12, 1.53)).
Based on the pattern of LD in the vicinity of rs11754661, we
examined several haplotypes of MTHFD1L which included this
SNP(described in Text S1)toidentify potential markers for untyped
variants associated with LOAD. Two haplotypes (the first
comprising rs2073066-rs11754661-rs13201018, the second com-
prising rs2839947-rs11757561-rs2073066-rs11754661-rs13201018)
both containing the risk-increasing A allele of rs11754661 had
highly statistically significant associations similar to the genotypic
association of rs11754661 (P~4:60|10{8 and P~6:54|10{8,
respectively) (Table S7). Both haplotypes had similar frequencies
(MHF) to the A allele of rs11754661 (MHF=0.0696 and
MHF=0.0629, respectively).
In order to ensure that the association we observed at
rs11754661 was not merely due to genotyping error, we genotyped
four additional SNPs in MTHFD1L proximal to and in high LD
(r
2.0.8) with rs11754661. All SNPs but one (rs7765521, P=0.055)
demonstrated associations with nominal statistical significance
Table 2. The strongest associations (P,10
25) from a GWAS of late-onset Alzheimer disease.
Discovery GWAS Replication GWAS Combined GWAS
SNP Chr Location Gene*** Function***
Minor
Allele
(Freq.)
OR* (95%
CI**) P
OR* (95%
CI**) P
OR* (95%
CI**) P
rs2075650 19 50087459 TOMM40 intron G (0.2) 2.96 (2.50,
3.50)
1.30610‘236 5.72 (3.63,
9.02)
6.24610‘214 2.94 (2.48,
3.47)
4.87610‘236
rs405509 19 50100676 APOE C (0.48) 0.62 (0.55,
0.70)
1.47610‘213 0.65 (0.49,
0.87)
0.00342 0.61 (0.54,
0.70)
8.13610‘214
rs8106922 19 50093506 TOMM40 intron G (0.36) 0.62 (0.54,
0.71)
3.10610‘212 0.79 (0.6,
1.05)
0.108 0.62 (0.54,
0.71)
2.94610‘212
rs157580 19 50087106 TOMM40 intron G (0.35) 0.66 (0.57,
0.75)
1.22610‘29 0.49 (0.36,
0.68)
0.0000153 0.63 (0.55,
0.71)
7.78610‘213
rs439401 19 50106291 LOC100129500 intron A (0.34) 0.66 (0.57,
0.75)
1.76610‘29 0.33 (0.22,
0.51)
4.23610‘27 0.63 (0.55,
0.72)
3.80610‘212
rs11754661 6 151248771 MTHFD1L intron A (0.07) 2.03 (1.58,
2.62)
4.70610‘28 2.34 (1.37,
3.98)
0.00187 2.10 (1.67,
2.64)
1.90610‘210
rs6859 19 50073874 PVRL2 intron A (0.46) 1.41 (1.24,
1.60)
1.06610‘27 1.70 (1.35,
2.13)
6.13610‘26 1.41 (1.24,
1.60)
9.60610‘28
rs10402271 19 50021054 C (0.36) 1.39 (1.22,
1.59)
7.26610‘27 1.23 (1.1,
1.38)
0.000277 1.26 (1.16,
1.38)
2.14610‘27
rs6509916 19 60254214 RDH13 intron G (0.46) 1.34 (1.18,
1.52)
5.83610‘26 0.87 (0.78,
0.98)
0.0223 1.10 (1.01,
1.20)
0.0334
rs509512 11 105350133 GRIA4 intron C (0.43) 0.75 (0.66,
0.85)
7.37610‘26 1.04 (0.94,
1.16)
0.439 0.94 (0.86,
1.02)
0.133
rs679670 6 138179244 G (0.37) 0.74 (0.65,
0.85)
9.83610‘26 1.11 (0.93,
1.34)
0.25 0.87 (0.78,
0.97)
0.016
*OR=Odds Ratio.
**CI=Confidence Interval.
***Gene Annotation using SNPper database [62].
Single nucleotide polymorphisms (SNPs) demonstrating association with late-onset Alzheimer Disease at P,10
25 in association tests adjusting for covariates from
principal components capturing population substructure, evaluated in the Discovery genome-wide association study (GWAS) dataset of 931 independent cases and
1,104 independent cognitively normal controls, in the Replication GWAS dataset of 1,242 independent cases and 1,737 independent controls, and in the Combined
GWAS dataset of 2,174 cases and 2,181 controls.
doi:10.1371/journal.pgen.1001130.t002
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P=0.035). Figure 2 shows the 2log10-transformed P-values for
single SNP tests of association in the MTHFD1L and 50kb flanking
region (151.2Mb–151.3Mb) surrounding the chromosome 6
association signal at rs11754661, among both SNPs genotyped
in the initial GWAS and those genotyped subsequently.
Association analyses of pooled datasets combining data on 1,242
cases and 1,737 controls confirmed experiment-wide statistically
significant associations for SNPs in/near APOE (replication from
P~6:24|10{14 to P=0.00187) for all but one SNP (rs8106922;
discovery P~3:10|10{12, replication P=0.108) (Table 2),
however the direction of association in the replication was
consistent across each of these SNPs. The association of the
MTHFD1L SNP rs11754661 in the replication was both
statistically significant (P=0.00187) and showed similar strength
and direction (discovery OR (95%CI): 2.03 (1.58, 2.62);
replication OR (95%CI): 2.34 (1.37, 3.98)).
Association in Combined Discovery and Replication
Datasets
In combined analyses, associations in and around the APOE
locus were unequivocally strengthened, with the p-values observed
ranging from P~3:8|10{12 to P~4:87|10{36. Variation at
rs11754461 was strongly associated (P~1:90|10{10) with an
elevated risk of LOAD with OR=2.10 (95% CI: 1.67, 2.64).
Several adjacent SNPs also demonstrated nominal associations
with similar direction of effect, including rs11757561
(P=0.000846) with OR=1.31 (95% CI: 1.12, 1.53) and
rs12195069 (P=0.0432) with OR=1.25 (95% CI: 1.01, 1.55).
Two SNPs with only modest statistical significance of association
in the discovery GWAS demonstrated highly statistically significant
association in analyses combining both discovery and replication
datasets (Tables S1 and S2). SNPs rs4676049 and rs17034806,
located at 109Mb on chromosome 2q13, had associations of
OR=1.62 (P~1:88|10{5) and OR=1.61 (P~2:66|10{5)
respectively in the discovery dataset. However, combiningdiscovery
and replication datasets, the SNP associations gained modest
strength in effect size (OR=1.76 for rs4676049 and OR=1.75 for
rs17034806), but the associations now exceeded the threshold for
experiment-wide statistical significance, with P~4:31|10{7 for
rs4676049 and P~5:14|10{8 for rs17034806.
Discussion
Although associations with experiment-wide statistical signifi-
cance have not been observed for MTHFD1L in previous GWAS
of LOAD, biological evidence suggests a role for this gene in
dementia and AD pathology. MTHFD1L, which encodes the
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-
like protein, is involved in tetrahydrofolate (THF) synthesis,
catalyzing the reversible synthesis of 10-formyl-THF to formate
and THF, an important step in homocysteine conversion to
methionine [26]. Elevated plasma homocysteine levels have been
implicated in AD [27,28] and other neurodegenerative disease
including Parkinson’s [29], and have been recognized as a risk
factor for pre-eclampsia [30], diabetic complications [31], and
heart disease [32]. Interestingly, a recent GWAS of coronary
artery disease (CAD) identified MTHFD1L as a CAD risk factor in
both British and German populations studied [33]. Several
potential mechanisms may explain this connection: hyperhomo-
cysteinaemia may influence AD dementia by causing vascular
alterations [34]; it may cause cholinergic deficit due to toxicity to
cortical neurons [35]; several lines of evidence suggest that
elevated homocysteine contributes to AD risk through increased
oxidative stress [36–38]. On-going biological investigations are
continuing to elucidate the pathways connecting elevated
homocysteine with AD.
Mthfd1l protein has been reported to be decreased in the
hippocampus in a mouse model of AD using a proteomic
approach [39]. Homocysteic acid, derived from homocysteine
and methionine, is elevated in these mice and treatment with
antibodies to homocysteic acid reduced amyloid burden and
inhibited cognitive decline in these animals [40]. B6-deficient diets
lead to further increases in homocysteic acid in these mice.
That we observed an experiment-wide statistically significant
association in MTHFD1L in addition to the associations of a
number of APOE SNPs with LOAD risk is consistent with results
from previous work. MTHFD1L is located on chromosome
6q25.1, near linkage signals observed in two prior genome-wide
linkage studies of LOAD [41,42]. The previous GWAS performed
by our group [18], from which nearly 1,000 individuals in the
current study were drawn, observed a strong, but not experiment-
wide, statistically significant association between the same
MTHFD1L SNP and LOAD at P=2.01610
25. Experiment-wide
statistical significance for this association was observed with the
addition of another 1,047 individuals in this study.
WedidnotobserveassociationswithLOADwith experiment-wide
statistical significance in any of the peak non-APOE signals identified
in previous GWAS studies, including the APOJ/CLU SNP
rs11136000 that was identified in both Harold et al. and Lambert
et al. studies (analysis of this dataset reported elsewhere (Jun et al., in
preparation)). Given the observed OR=0.86 of rs11136000 for
LOAD, in our sample of 931 cases and 1,104 controls, we had ,1%
power to detect the observed effect at the Bonferroni-corrected
threshold for experiment-wide statistical significance, a=1.03 610
27,
suggesting that most significant associations of small or modest effect
size would be missed in this study. The association of variation in
PCDH11X and GAB2 was not observed in this dataset; the findings of
theseanalyses are reported elsewhere [43]. In addition, we observed a
strong association of the chromosome 12 SNP rs11610206 with
LOAD, but not with genomewide statistical significance as observed
in our previous GWAS [18], suggesting that the findings of the
Beechamet al.study, as withprevious LOADGWAS, may besubject
to the ‘‘winner’s curse’’ [44].
Despite a wealth of evidence for the role of chromosome 2 loci
in Alzheimer’s Disease, the chromosome 2q13 SNPs identified
with experiment-wide statistically significant associations in the
combined analyses, rs4676049 and rs17034806, do not fall in the
vicinity of chromosome 2 regions of interest [22,45].
Based on the patterns of studies emerging in other complex
diseases, GWAS studies with sample sizes greater than the
combined Lambert et al. and Harold et al. datasets may be
necessary to validate associations observed in smaller GWAS
studies and to identify susceptibility variants with more modest
effects. This approach has been taken in type 2 diabetes, where a
meta-analysis of 54,000 subjects confirmed multiple susceptibility
Figure 1. Quantile-Quantile plots for 483,399 single SNP tests of association. Plots depict expected versus observed 2log10 P-values for
483,399 single SNP tests of association (in 931 LOAD cases and 1,104 cognitive controls, with adjustment for principal components as covariates for
population substructure). Plot A includes the most-strongly associated SNPs within the APOE locus, whereas plot B excludes the three most-strongly
associated SNPs for clarity.
doi:10.1371/journal.pgen.1001130.g001
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are exploring the Common Disease-Rare Variants (CDRV)
hypothesis, which aim to identify novel susceptibility loci for
disease by assessing the aggregate effects of multiple rare variants
in single genes on disease risk [46].
In this genome-wide association study of LOAD, we identified a
novel association with experiment-wide statistical significance in a
gene with a potential biological role, MTHFD1L. We replicated
this association in additional publicly-available genomewide
association datasets, and observed statistically significant associa-
tion with a similar effect size and direction at this SNP. In
summary, MTHFD1L is an excellent candidate for LOAD on
account of its involvement in folate-pathway abnormalities linked
with homocysteine, a significant biological risk factor for AD.
Methods
Ethics Statement
After complete description of the study to the subjects, written
informed consent was obtained from all participants, in agreement
with protocols approved by the institutional review board at each
contributing center.
Ascertainment
Discovery dataset cases and controls were clinically ascertained
through the Collaborative Alzheimer’s Project (CAP) comprising
the University of Miami John P. Hussman Institute for Human
Genomics (HIHG) and the Vanderbilt University Center for
Human Genetics Research (CHGR), and autopsy-verified cases
and controls were collected through the Mount Sinai Brain Bank
(MSBB) at the Mount Sinai School of Medicine (see [47]).
Additional controls were also identified in the National Cell
Repository for Alzheimer’s Disease (NCRAD). 266 cases and 643
controls genotyped in the discovery dataset from the NCRAD,
HIHG, and CHGR [48] and NCRAD were independent from
previously published data sets including those from our group’s
previously published GWAS [18]. All CAP-ascertained cases and
controls were recruited and evaluated using standardized criteria
and protocols, and case adjudication in the CAP was performed
jointly by a Clinical Advisory Board (CAB) composed of both
Figure 2. Manhattan plot of SNP associations in MTHFD1L, on chromosome 6 between 151.2 Mb and 151.3 Mb. Plot of 2log10 P-values
for single SNP tests of association with LOAD with adjustment for population substructure for the chromosome 6 region from 151.2Mb to 151.3Mb in
MTHFD1L. Blue circles depict results for SNPs examined as part of genomewide association testing, whereas the green circle depicts the genome wide
significant association of rs11754661 and the green triangles show the association results of the additional six SNPs proximal to rs11754661
genotyped on the Taqman platform. The orange line below the x-axis depicts the exons (thick line) and introns (thin line) of the MTHFD1L, oriented 59
to 39 from left to right.
doi:10.1371/journal.pgen.1001130.g002
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as well.
All cases and controls from the HIHG, CHGR, and NCRAD
met selection criteria described in the Beecham et al. study [18].
Briefly, the study was described and written informed consists were
obtained from all participants, in accordance with institutional
review board protocols at each study center. Each individual
classified as a LOAD case met the NINCDS-ADRDA criteria for
probable or definite AD and had an age at onset greater than 60
years of age [49], as determined from specific questions within the
clinical history answered by a reliable family informant or from
documented significant cognitive impairment in the medical record.
Vascular dementia was diagnosed according to contemporary
standards [50] by the CAB, and individuals withconfirmed vascular
dementia or phenotypic uncertainty were excluded from analyses.
Cognitive controls were individuals who showed signs of dementia
in clinical history or upon interview, and were drawn from spouses,
friends, and other biologically unrelated individuals of cases, were
frequency-matched by age and gender to the cases, and were
located in the same clinical catchment areas. All cognitive controls
were examined, and none showed signs of dementia in clinical
history or upon interview. Also, each cognitive control had a
documented Mini-Mental State Exam (MMSE) score $27 or a
Modified Mini-Mental State (3MS) Exam score $87. Clinical
history and interview data for NCRAD controls, including MMSE
scores, were made available and collected along with whole blood
for DNA extraction for inclusion in our study.
306 cases and 81 controls identified in the MSBB were recently
deceased patients at the Mount Sinai Medical Center in New
York, NY, and had affection status verified through clinical review
and brain autopsy. Neither the cases nor controls examined have
been used in previously published studies. Covariates including
age at death and sex were abstracted from reviews of medical
charts performed by members of the MSBB.
In total, 572 new cases and 724 new controls were genotyped in
this study, and after quality controls measures, combined with data
on 492 cases and 496 controls from the previous GWAS [18] for
analysis. We also had available for replication from the HIHG, a
dataset of 246 cases and 69 cognitively normal controls from a
previously described dataset [51].
Genotyping
We extracted DNA for individuals ascertained by the HIHG,
CHGR, MSBB, and NCRAD from whole blood by using Puregene
chemistry (QIAGEN, Germantown, MD, USA). We performed
genotypingusingtheIlluminaBeadstationandtheIlluminaInfinium
Human 1M beadchip on 530 cases and 393 controls following the
recommended protocol, only with a more stringent GenCall score
threshold of 0.25. Genotyping on 248 controls from the PD GWAS
dataset[48]wasperformedusingtheIlluminaInfiniumHuman610-
Quad beadchip. Genotyping efficiency was greater than 99%, and
quality assurance was achieved by the inclusion of one CEPH
control per 96-well plate that was genotyped multiple times.
Technicians were blinded to affection status and quality-control
samples. We used Taqman Genotyping Assays for SNPs +3937/
rs429358 and +4075/rs7412 and performed allelic discrimination/
genotype calling on the ABI 7900 Taqman system, the results of
which were used to determine APOE e2/e3/e4 genotypes.
After excluding samples which failed quality control (described
in the next section) with low genotyping call rates, genotype data
was available on 870,954 SNPs (after quality control) using the
Illumina 1M BeadChip on 440 cases and 437 controls, while
genotype data on 490,960 SNPs (after quality control) from the
Illumina 610Quad BeadChip was available on 172 controls.
Combining these data with the 522,366 SNPs on 492 cases and
496 controls in our previous GWAS [18], a set of 483,399 SNPs
common to all platforms was generated that passed quality control
for each subset individually and in a pooled dataset. The
Bonferroni-corrected threshold for experiment-wide statistical
significance was thus set at Bonferroni-corrected a~1:03|10{7.
Sample Quality Control
After genotyping, multiple quality controls were performed
including assessment of sample efficiency, which is the proportion
of valid genotype calls to attempted calls within a sample. Samples
with efficiency less than 0.98 were dropped from the analysis.
Reported gender and genetic gender were examined with the use
of X-linked SNPs; 32 inconsistent samples were dropped from the
analysis. Relatedness between samples was tested via the program
Graphical Representation of Relatedness (GRR) [52], and 3
related samples were dropped from the analysis.
To determine if population substructure exists in the case-control
sample, a set of 10,000 SNPs with MAF.0.25, selected for minimal
between-SNP linkage disequilibrium (r
2,0.20), and spread evenly
across the autosomal chromosomes were analyzed using the program
STRUCTURE [53,54] (burn in: 5,000, iterations: 25,000) assuming
differentnumber of assumedsubpopulations (K).The 2loglikelihood
for K was maximized at K=3, suggesting population substructure.
Further analysis was performed in EIGENSTRAT [55], where
principal components analysis on the sample of 10,000 SNPs was
used to generate principal component loadings for samples and
remove outliers by using the top ten principal components over 5
iterations with a threshold of six standard deviations. The top three
principal component loadings were used as covariates to account for
population structure in the association analysis.
Removing genotyped individuals with low genotype call rates,
incorrect reported gender, high relatedness with other samples,
and extreme outliers in substructure analyses, 440 cases and 608
controls remained for inclusion in analysis, and were combined
with 492 cases and 496 controls from the previous GWAS.
SNP Quality Control
Quality control was performed to remove any low quality SNPs.
Genotype clusters were redefined using signal intensities of
samples with efficiency greater than 0.98, and genotypes were
recalled on the basis of these new clusters per the manufacturer’s
recommendation. Efficiency of individual SNPs was estimated as
the proportion of samples with genotype calls for a given SNP, and
SNPs with efficiency less than 0.95 were dropped from analysis.
Due to concerns of low statistical power to detect association,
SNPs with MAF,0.005 were dropped from analysis. Hardy-
Weinberg Disequilibrium (HWD) statistics were calculated among
controls with the Fisher’s exact test in the PLINK software
package [56]; SNPs with P,10
26 for HWD were dropped from
analysis. In addition, due to concerns with the spurious association
originating from the use of different genotyping platforms on
samples in the previous and current GWAS studies, distributions
of genotype frequencies at each SNP in each study were examined
among controls using a Fisher’s exact test, and SNPs with highly-
differing genotype distributions across genotyping subsets
(P,0.001) were dropped prior to analysis. After these quality
control measures, 483,399 SNPs remained for association analysis.
Association Analysis
Association analysis was performed using logistic regression to test
association of genotypes with LOAD under an additive model.
Logistic regression was used to permit covariate adjustment for
loadings taken from the first three principal components identified in
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report results from logistic regression models adjusting only for
population substructure with principal components. Further regres-
sion modeling was also performed on SNPs with initial associations
of P,10
25, extending models to adjust for APOE genotype
(designated as the number of e4 alleles), age-at-onset in cases and
age-at-exam in controls, and gender as covariates (Table S6). All
analyses were performed using the PLINK software package [56].
Quantile-quantile plots of the associations were made (Figure 1),
and suggest the absence of systematic bias in the tests of
association.
Imputation and Replication Analysis
To provide independent replication of the associations observed
in the discovery dataset, genome-wide genotyping data were
combined from four additional datasets (one unpublished and
three publicly-available datasets) and missing genotype data
imputed using IMPUTE v1.0 [57] (Table S8). SNPs with differing
genotypic distributions between datasets were excluded from
imputation using the Fisher’s exact test approached described
earlier [58]. Both primary and replication datasets were imputed
to a HapMap reference of over 2.5 million SNPs. Individual
genotypes with probability less than 0.90 were not included, and
SNPs missing .10% of genotypes within either data set were
dropped. In addition to using the combined Hapmap Phase III
CEPH Utah pedigree (CEU) and Tuscan (TSI) haplotype
reference panels for imputation, for imputation within each study,
we used genotype data on controls from other datasets to improve
imputation accuracy, and Affymetrix 5.0 genotype data on 105
individuals genotyped in an independent Ashkenazi Jewish
genotyping panel [59].
We analyzed existing pooled and imputed datasets of unrelated
individuals from several studies: 147 cases and 182 controls from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [60], 86
cases and 1,200 controls (all unrelated) from the Framingham
Study SHARe dataset [61], and 859 cases and 552 controls from
the Reiman et al. [15] LOAD GWAS dataset, and a set of 246
LOAD cases and 69 cognitively normal controls previously
described [51] and genotyped on the Affymetrix 6.0 genotyping
platform on which results have not been previously published.
Supporting Information
Figure S1 Plots of 2log10 P-values for 483,399 single SNP tests
of association (in 931 LOAD cases and 1,104 cognitive controls,
with adjustment for principal components as covariates for
population substructure). Plot A includes association results from
all SNPs within the APOE locus, whereas plot B excludes the three
most strongly associated SNPs for clarity.
Found at: doi:10.1371/journal.pgen.1001130.s001 (3.45 MB TIF)
Figure S2 LD (Plot A: D’, Plot B: r
2) between 130 SNPs
genotyped in 931 cases and 1,104 controls in and around the gene
MTHFD1L (650 kilobasepairs). The SNP with the most signifi-
cant association, rs11754661, is highlighted with a blue arrow in
the diagram below.
Found at: doi:10.1371/journal.pgen.1001130.s002 (2.01 MB TIF)
Table S1 Single nucleotide polymorphisms (SNPs) demonstrat-
ing association with late-onset Alzheimer Disease at P,10
24 in
association tests adjusting for covariates from principal compo-
nents capturing population substructure, evaluated in the
Discovery genome-wide association study (GWAS) dataset of
931 independent cases and 1,104 independent cognitively normal
controls, in the Replication GWAS dataset of 1,242 independent
cases and 1,737 independent controls, and in the Combined
GWAS dataset of 2,174 cases and 2,181 controls.
Found at: doi:10.1371/journal.pgen.1001130.s003 (0.11 MB
DOC)
Table S2 Genotyped and imputed single nucleotide polymor-
phisms (SNPs) demonstrating association with late-onset Alzhei-
mer Disease at P,10
24 in association tests adjusting for covariates
from principal components capturing population substructure,
evaluated in the Discovery genome-wide association study
(GWAS) dataset of 931 independent cases and 1,104 independent
cognitively normal controls, in the Replication GWAS dataset of
1,242 independent cases and 1,737 independent controls, and in
the Combined GWAS dataset of 2,174 cases and 2,181 controls.
Found at: doi:10.1371/journal.pgen.1001130.s004 (0.30 MB
DOC)
Table S3 Follow-up of the strongest associations reported in the
Beecham, et al.(2009) [18] GWAS of late-onset Alzheimer
Disease. 32 single nucleotide polymorphisms (SNPs) demonstrat-
ing the strongest association with late-onset Alzheimer Disease at
P,10
25 in the Beecham et al. (2009) [18] GWAS of late-onset
Alzheimer’s Disease, tested here for association with adjustment
for covariates from principal components capturing population
substructure, evaluated in the Discovery genome-wide association
study (GWAS) dataset of 931 independent cases and 1,104
independent cognitively normal controls.
Found at: doi:10.1371/journal.pgen.1001130.s005 (0.06 MB
DOC)
Table S4 Genotype frequency distributions and differences in
three subsets of a GWAS dataset for SNPs with strong associations
with late-onset Alzheimer Disease. Genotype counts, P-values for
Hardy-Weinberg Equilibrium (HWE), and P-values for differences
in genotypic distribution from a Fisher’s Exact Test (FET)
comparing controls in SNPs with strong associations with late-
onset Alzheimer Disease in three subsets of a GWAS dataset:
cognitively normal controls from the previously published
Beecham et al (2009) study [18] (‘‘Beecham et al. controls’’),
cognitively normal controls recruited after the Beecham et al.
(2009) study (‘‘New AD Controls’’), and cogntively normal controls
consented for multiple genetic studies whose recruitment was
funded through the Udall Parkinson’s Disease Collaboration
(‘‘Udall Controls’’).
Found at: doi:10.1371/journal.pgen.1001130.s006 (0.05 MB
DOC)
Table S5 Demographic characteristics of participants, subsetted
by study center, autopsy or clinical confirmation of case or control
status, and by genotyping platform (mean 6 SD or number
(percent)).
Found at: doi:10.1371/journal.pgen.1001130.s007 (0.07 MB
DOC)
Table S6 Changes in effect size and p-value with additional
covariate adjustment for age, sex, and presence/absence of the
APOE e4 allele for SNP associations demonstrating P,10
25 in
preliminary analyses of late-onset Alzheimer Disease. SNPs
demonstrating association with late-onset Alzheimer Disease at
P,10
25 as identified in Table 2, here showing results from
logistic regression modeling with (1) no additional covariate
adjustment, (2) additional covariate adjustment for age-at-onset
(years, in cases only) and age-at-exam (years, in controls only) and
sex, and (3) additional covariate adjustment for age-at-onset
(years, in cases only) and age-at-exam (years, in controls only);
sex; and presence presence/absence of the APOE e4 allele. All
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components capturing population substructure.
Found at: doi:10.1371/journal.pgen.1001130.s008 (0.04 MB
DOC)
Table S7 Associations with late-onset Alzheimer Disease of
MTHFD1L haplotypes incorporating SNP rs11754661, with
adjustment for covariates from principal components capturing
population substructure, evaluated in the Discovery GWAS
dataset of 931 independent cases and 1,104 independent
cognitively normal controls.
Found at: doi:10.1371/journal.pgen.1001130.s009 (0.03 MB
DOC)
Table S8 Genotyping or imputation of SNPs associated with
LOAD at P,10
24. Index indicating whether single nucleotide
polymorphisms (SNPs) demonstrating association with late-onset
Alzheimer Disease at P,10
24 in association tests adjusting for
population substructure in the Discovery dataset where genotyped
or imputed in the Discovery dataset (931 independent cases and
1,104 independent cognitively normal controls) or any of the
Replication datasets, including the from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) [60] (147 cases and 182 controls),
the Framingham Study SHARe dataset (SHARe) [61] (86 cases
and 1,200 controls (all unrelated)), the Reiman, et al., LOAD
GWAS dataset (TGEN) [15] (859 cases and 552 controls), and an
additional set of LOAD cases and controls independent of the
Discovery dataset and not used in prior publications (ADRC) [51]
(246 LOAD cases and 69 cognitively normal controls).
Found at: doi:10.1371/journal.pgen.1001130.s010 (0.24 MB
DOC)
Text S1 Supplementary methods describing haplotype analyses.
Found at: doi:10.1371/journal.pgen.1001130.s011 (0.02 MB
DOC)
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